225-Actinium-AZD-2284

N/A

Report date: 2026/01/04 10:45:53

Base Information

Drug Name225-Actinium-AZD-2284

Drug Alias NameAZD2284AZD-2284[225Ac]-AZD2284

ClassificationRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Actinium > 225AcRadiation-emitting products > Radionuclide Drug Conjugates

Mechanisms of ActionSix-transmembrane epithelial antigen of the prostate 2 inhibitors

TargetsSix-transmembrane epithelial antigen of the prostate 2

Therapy Area/IndicationsProstatic Neoplasms, Castration-Resistant

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesSouth AfricaAustralia

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesAstrazeneca Plc

China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca Plc

Inactive CompaniesN/A

Active IndicationsProstatic Neoplasms, Castration-Resistant

Inactive IndicationsN/A

Other Information

ATC CodeN/A